Defining Value for the Treatment of Brain Metastases in Metastatic HER2-Positive Breast Cancer

Sarah Sammons, MD, provides an overview of the progression HER2-positive metastatic breast cancer [mBC] and common areas for the development of metastases, including in the brain.

Insights on diagnosing patients who have HER2+ metastatic breast cancer with brain metastases based on current NCCN Guidelines recommendations when they may present with them during the course of treatment, and the impact on quality of life.

Kevin M. Kalinsky, MD, MS, discusses monitoring patients with HER2-positive mBC who have asymptomatic brain metastases and advancements in therapy for HER2-positive disease leading to increased brain metastases.

Sarah Sammons, MD, and Bhavesh Shah, RPh, BCOP, discuss the increase in health care resource utilization associated with brain metastases for HER2-positive mBC.

Exploring current advances in treatment options beyond the second-line setting for progressive HER2-positive metastatic breast cancer.

The goals of therapy and unmet needs for patients with HER2-positive metastatic breast cancer at risk for brain metastases are examined.

A review of the HER2CLIMB study using oral the TKI tucatinib as therapy for HER2-positive metastatic breast cancer.

Sarah Sammons, MD, and Kevin M. Kalinsky, MD, MS, review the phase 2 LANDSCAPE trial using lapatinib for patients with HER2+ mBC and a history of brain metastases.

A review of the NALA study looking at the use of capecitabine plus neratinib in patients with pretreated metastatic HER2-positive breast cancer.

Kevin M. Kalinsky, MD, MS, and Sarah Sammons, MD, review the phase 2 single-arm trial DESTINY-Breast01, exploring the use of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer.

Bhavesh Shah, RPh, BCOP, defines the value for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer.

Comparing and contrasting the safety and efficacy of agents when approaching treatment of brain metastases in HER2-positive mBC.

A payer and provider perspective on treating all patients with HER2-positive mBC as if they are at risk for brain metastases and the use of clinical pathways to ensure the correct patients are treated.

A payer perspective on the impact of early identification of brain mets in HER2+ metastatic breast cancer on healthcare utilization and patient outcomes as well as recommendations to other payers managing this patient population.

The role of patient-centered value-based care models in the treatment of brain metastases in HER2+ mBC and the importance of patient support services.

Bhavesh Shah, RPh, BCOP, provides a payer perspective on the impact of COVID-19 on site of care for patients with metastatic breast cancer and the role of value-based contracting for the future.

The impact of COVID-19 on the treatment of metastatic breast cancer in regard to site of care and utilization of telehealth, as well as the evolving treatment landscape with emerging agents in the pipeline.